A Study Evaluating The Safety Of PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-06)

Completed · Phase 1

Conditions studied: Healthy

In brief

This study is to prove that there is no difference in the number of healthy male volunteers that will experience pyrexia (i.e. fever with body temperature of 38°C or higher) within a 24 hour period after administration of a single dose of 6mg/kg of PF-05280014 or trastuzumab sourced from the United States (trastuzumab-US). The study will also compare the safety of both drugs.

Key facts

Study ID

NCT02015156

Run by

Pfizer

People needed

162

Starts

2014-01-01

Expected to finish

2014-04-01

Last updated by the study team

2014-04-23

Who can join

Age: 18 and older, up to 55. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Body Mass Index (BMI) of 17.5 to 30.5 kg\^m2; and a total body weight >50 kg (110 lbs).
• Left ventricular ejection fraction (LVEF) within the normal range as measured by echocardiogram (ECHO) within 8 weeks prior to randomization.
• Subjects who have previously been exposed to a biologic agent (other than a HER2 inhibitor) may enroll provided that at least 3 months have passed since the last administration of that drug.

You may not qualify if…

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• Previous exposure to an anti-HER2 antibody.
• History of serious allergic or anaphylactic reaction to a therapeutic drug or benzyl alcohol.

Where it is running

• Pfizer Investigational Site — Overland Park, Kansas, United States
• Pfizer Investigational Site — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.